A Phase I Study Of Low-Dose Subcutaneous Interleukin 2 (IL-2) And Stem Cell Factor (r-metHuSCF) For Patients With AIDS And AIDS-Associated Malignancy
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Interleukin-2; Stem cell factor
- Indications Cancer
- Focus Adverse reactions
- 31 Jan 2013 Biomarkers information updated
- 25 Oct 2007 Status changed from in progress to recruiting.
- 10 Oct 2005 New trial record.